Seaport Therapeutics
@seaporttx.bsky.social
We're a clinical-stage biopharmaceutical company advancing the development of neuropsychiatric medicines in areas of high unmet patient needs.
Today Co-Founder & Board Chair Dr. Steve Paul joins Technology Innovation Studio’s Breakthrough Biotech Builders fireside chat on his role in the dev of CNS blockbusters Zyprexa®, Cymbalta® and Cobenfy™ (KarXT) which originated at PureTech (founded/led by @daphnezohar.bsky.social) luma.com/5rfgvqfd
Breakthrough Biotech Builders: Session with Steve Paul · Luma
This discussion would be a private gathering designed to foster high-level dialogue and genuine connections in the area of biotech leadership. We hope that…
luma.com
November 19, 2025 at 8:31 PM
Today Co-Founder & Board Chair Dr. Steve Paul joins Technology Innovation Studio’s Breakthrough Biotech Builders fireside chat on his role in the dev of CNS blockbusters Zyprexa®, Cymbalta® and Cobenfy™ (KarXT) which originated at PureTech (founded/led by @daphnezohar.bsky.social) luma.com/5rfgvqfd
Thanks to the NEVYs for nominating us for the Powerhouse Healthcare Company of the Year at the #NEVYs25Awards! Great progress this year w/ the launch of two clinical trials & we look forward to making a difference for those w/ #neuropsychiatric conditions: bit.ly/nevy25
November 14, 2025 at 3:06 PM
Thanks to the NEVYs for nominating us for the Powerhouse Healthcare Company of the Year at the #NEVYs25Awards! Great progress this year w/ the launch of two clinical trials & we look forward to making a difference for those w/ #neuropsychiatric conditions: bit.ly/nevy25
Tune in today at 10:00AM EST as our CFO, Lauren White, & CSO, Michael Chen, present at the Stifel 2025 Healthcare Conference. The team will also participate in 1x1 meetings while at the conference.
Tune in: bit.ly/4oNTUBA
Replay available here: bit.ly/43Nvu33
Tune in: bit.ly/4oNTUBA
Replay available here: bit.ly/43Nvu33
November 11, 2025 at 12:00 PM
Tune in today at 10:00AM EST as our CFO, Lauren White, & CSO, Michael Chen, present at the Stifel 2025 Healthcare Conference. The team will also participate in 1x1 meetings while at the conference.
Tune in: bit.ly/4oNTUBA
Replay available here: bit.ly/43Nvu33
Tune in: bit.ly/4oNTUBA
Replay available here: bit.ly/43Nvu33
Members of our management team will present at the Stifel 2025 Healthcare Conference on November 11 at 10:00AM ET. The team will also participate in 1x1 meetings during the conference.
Press release: bit.ly/49x28cP
Live & archived webcast here: seaporttx.com/news-papers/
Press release: bit.ly/49x28cP
Live & archived webcast here: seaporttx.com/news-papers/
November 4, 2025 at 12:01 PM
Members of our management team will present at the Stifel 2025 Healthcare Conference on November 11 at 10:00AM ET. The team will also participate in 1x1 meetings during the conference.
Press release: bit.ly/49x28cP
Live & archived webcast here: seaporttx.com/news-papers/
Press release: bit.ly/49x28cP
Live & archived webcast here: seaporttx.com/news-papers/
Happy Halloween! We had so much fun celebrating together w/ themed team costumes & plenty of laughs. These gatherings remind us how connection energizes our shared commitment to developing new medicines for people living w/ #neuropsychiatric conditions like #depression & #anxiety.
October 31, 2025 at 6:09 PM
Happy Halloween! We had so much fun celebrating together w/ themed team costumes & plenty of laughs. These gatherings remind us how connection energizes our shared commitment to developing new medicines for people living w/ #neuropsychiatric conditions like #depression & #anxiety.
Co-Founder & CEO, @daphnezohar.bsky.social joined an all-women Rare & Neuro Diseases panel at #USAIC25 (watch: bit.ly/3LcJkWg) & gave a shoutout to the Biotech CEO Sisterhood in her opening remarks (view: bit.ly/3X1WPKY).
Join us at #USAIC26: bit.ly/4oEvmei
Join us at #USAIC26: bit.ly/4oEvmei
October 28, 2025 at 11:00 AM
Co-Founder & CEO, @daphnezohar.bsky.social joined an all-women Rare & Neuro Diseases panel at #USAIC25 (watch: bit.ly/3LcJkWg) & gave a shoutout to the Biotech CEO Sisterhood in her opening remarks (view: bit.ly/3X1WPKY).
Join us at #USAIC26: bit.ly/4oEvmei
Join us at #USAIC26: bit.ly/4oEvmei
“We Own It” is a core value of ours & captures our entrepreneurial spirit. Co-Founder & CEO, @daphnezohar.bsky.social, shows us how it's done. Named a Goldman Sachs Most Exceptional Entrepreneur, she inspires us to push boundaries so we can best serve those with #neuropsychiatric conditions.
October 17, 2025 at 11:01 AM
“We Own It” is a core value of ours & captures our entrepreneurial spirit. Co-Founder & CEO, @daphnezohar.bsky.social, shows us how it's done. Named a Goldman Sachs Most Exceptional Entrepreneur, she inspires us to push boundaries so we can best serve those with #neuropsychiatric conditions.
Board member, Denice Torres, shared her expertise on happiness, a core value & key to our work. We aim to increase happiness worldwide & develop novel medicines for #neuropsychiatric conditions. This #WorldMentalHealthDay, we’re reminded that happiness & mental health are linked.
October 10, 2025 at 11:01 AM
Board member, Denice Torres, shared her expertise on happiness, a core value & key to our work. We aim to increase happiness worldwide & develop novel medicines for #neuropsychiatric conditions. This #WorldMentalHealthDay, we’re reminded that happiness & mental health are linked.
Members of our exec team joined Fierce Biotech’s #Fierce15 awards to celebrate our recognition, honoring our team's work developing new medicines for #depression & #anxiety. It's also a reflection of the strong momentum & growth since our launch last year. bit.ly/3VSOQQ7
October 9, 2025 at 6:36 PM
Members of our exec team joined Fierce Biotech’s #Fierce15 awards to celebrate our recognition, honoring our team's work developing new medicines for #depression & #anxiety. It's also a reflection of the strong momentum & growth since our launch last year. bit.ly/3VSOQQ7
We convened top neuropsych experts, sell-side analysts, investors, & biopharma leaders for a unique roundtable discussion on the opportunities & excitement in #neuropsychiatry & what’s next as #MentalHealth conditions continue to impact millions globally. See below for some takeaways
October 8, 2025 at 11:02 AM
We convened top neuropsych experts, sell-side analysts, investors, & biopharma leaders for a unique roundtable discussion on the opportunities & excitement in #neuropsychiatry & what’s next as #MentalHealth conditions continue to impact millions globally. See below for some takeaways
Tune in today at 11:45 AM ET to hear our CFO Lauren White & COO Eric Green present at the Oppenheimer Private Life Sciences Company Showcase. Live webcast: bit.ly/4nllNke & replay available on our website: seaporttx.com/news-papers/
September 25, 2025 at 11:00 AM
Tune in today at 11:45 AM ET to hear our CFO Lauren White & COO Eric Green present at the Oppenheimer Private Life Sciences Company Showcase. Live webcast: bit.ly/4nllNke & replay available on our website: seaporttx.com/news-papers/
We’re a Fierce Biotech Fierce 15 winner! Our Glyph platform, proven team, & focus on validated mechanisms put us among the most “innovative & visionary” companies as we advance clinical programs aiming to deliver new medicines for #depression & #anxiety. bit.ly/4msojnm
September 22, 2025 at 4:02 PM
We’re a Fierce Biotech Fierce 15 winner! Our Glyph platform, proven team, & focus on validated mechanisms put us among the most “innovative & visionary” companies as we advance clinical programs aiming to deliver new medicines for #depression & #anxiety. bit.ly/4msojnm
Looking forward to two upcoming investor conferences: 1x1s & company presentation at Oppenheimer's Private Life Sciences Company Showcase on 9/25 at 11:45am ET & 1x1s at the 5th Annual Needham Private Biotech & MedTech Company Forum, held 10/14-10/15. bit.ly/42z6Fr1
September 18, 2025 at 11:04 AM
Looking forward to two upcoming investor conferences: 1x1s & company presentation at Oppenheimer's Private Life Sciences Company Showcase on 9/25 at 11:45am ET & 1x1s at the 5th Annual Needham Private Biotech & MedTech Company Forum, held 10/14-10/15. bit.ly/42z6Fr1
Pleased to share the first participant has been dosed in our Ph1 study of GlyphAgo™ (SPT-320). This is our 2nd therapeutic candidate in clinical development & represents an important clinical advancement for patients w/GAD. bit.ly/4meQFl0
September 11, 2025 at 11:09 AM
Pleased to share the first participant has been dosed in our Ph1 study of GlyphAgo™ (SPT-320). This is our 2nd therapeutic candidate in clinical development & represents an important clinical advancement for patients w/GAD. bit.ly/4meQFl0
Dan Bonner, Co-Founder & SVP, Platform at Seaport will present at the Neuropsychiatric Drug Development Summit in Boston on 9/11 at 1:30pm to share insights on the discovery & selection of novel lymphatic-targeted prodrug candidates using clinical evidence ter.li/42ap36
September 9, 2025 at 1:14 PM
Dan Bonner, Co-Founder & SVP, Platform at Seaport will present at the Neuropsychiatric Drug Development Summit in Boston on 9/11 at 1:30pm to share insights on the discovery & selection of novel lymphatic-targeted prodrug candidates using clinical evidence ter.li/42ap36
Congrats to COBENFY & ZURZUVAE teams for 2025 #PrixGalien Best Pharmaceutical Product noms! Kudos to all involved (@PureTechh, Karuna for COBENFY) in the successful journeys, notably Seaport's Dr. Steve Paul for his role in advancing both nominated drugs bit.ly/3V6cx72
September 9, 2025 at 1:10 PM
Congrats to COBENFY & ZURZUVAE teams for 2025 #PrixGalien Best Pharmaceutical Product noms! Kudos to all involved (@PureTechh, Karuna for COBENFY) in the successful journeys, notably Seaport's Dr. Steve Paul for his role in advancing both nominated drugs bit.ly/3V6cx72
This summer, the team had a blast together building meaningful connections. From everyday moments to unique outings, these experiences reinforce our bonds & remind us of our shared mission to serve those with #MentalHealth conditions like #depression & #anxiety. Excited for more!
August 28, 2025 at 6:47 PM
This summer, the team had a blast together building meaningful connections. From everyday moments to unique outings, these experiences reinforce our bonds & remind us of our shared mission to serve those with #MentalHealth conditions like #depression & #anxiety. Excited for more!
We're featured in @natbiotech.nature.com's “Editor’s Pick” for our work developing #neuropsychiatric medicines using our proprietary Glyph platform. Read about how we're advancing novel therapies with clinically validated mechanisms for depression & anxiety bit.ly/47f4jke
Each year, we highlight companies that received sizeable early-stage funding in the previous year. @seaporttx.bsky.social is modifying central nervous system drugs for delivery through the lymphatic system, bypassing first-pass liver metabolism
Editor’s Pick: Seaport Therapeutics - Nature Biotechnology
Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Seaport Therapeutics is modifying central nervous system drugs for delivery throug...
go.nature.com
August 4, 2025 at 5:11 PM
We're featured in @natbiotech.nature.com's “Editor’s Pick” for our work developing #neuropsychiatric medicines using our proprietary Glyph platform. Read about how we're advancing novel therapies with clinically validated mechanisms for depression & anxiety bit.ly/47f4jke
Our CFO, Lauren White, joins Boston Business Journal's “Biotech’s Future – Innovation, AI and our Competitive Edge” panel this Thursday with other industry leaders to discuss the future of biotech & life sciences in MA. Don’t miss this dynamic discussion! bit.ly/44VDFLK
July 30, 2025 at 11:00 AM
Our CFO, Lauren White, joins Boston Business Journal's “Biotech’s Future – Innovation, AI and our Competitive Edge” panel this Thursday with other industry leaders to discuss the future of biotech & life sciences in MA. Don’t miss this dynamic discussion! bit.ly/44VDFLK
CEO @daphnezohar.bsky.social took Brad Loncar @biotechtv.bsky.social on a tour of our office located in heart of Boston’s Seaport District, which is uniquely designed to foster collaboration, happiness & teamwork as we work together to develop new medicines for #depression & #anxiety. Check it out!
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐓𝐨𝐮𝐫: BiotechTV visited the new offices of @seaporttx.bsky.social today and was given a tour by Founder & CEO @daphnezohar.bsky.social
July 22, 2025 at 11:36 AM
CEO @daphnezohar.bsky.social took Brad Loncar @biotechtv.bsky.social on a tour of our office located in heart of Boston’s Seaport District, which is uniquely designed to foster collaboration, happiness & teamwork as we work together to develop new medicines for #depression & #anxiety. Check it out!
For @biotechtv.bsky.social's Biotech CEO Sisterhood series, our CEO @daphnezohar.bsky.social spoke to Sophie Kornowski on her journey leading Boston Pharmaceuticals to a $2B deal w/ GSK. Check this out for insights from both leaders on dealmaking, leadership strategies & mentorship: bit.ly/4m55kzG
Biotech CEO Sisterhood: As CEO, Sophie Kornowski sold Boston Pharmaceuticals to GSK earlier this year for up to $2 billion. She shares her thoughts on the biopharma business and leadership
Interviewed by Sisterhood editorial board member Daphne Zohar, Sophie Kornowski shares her keys to creating great assets, commercialization, partnerships, and, ultimately, executing a successful deal ...
bit.ly
July 18, 2025 at 5:44 PM
For @biotechtv.bsky.social's Biotech CEO Sisterhood series, our CEO @daphnezohar.bsky.social spoke to Sophie Kornowski on her journey leading Boston Pharmaceuticals to a $2B deal w/ GSK. Check this out for insights from both leaders on dealmaking, leadership strategies & mentorship: bit.ly/4m55kzG
Pleased to announce the first patient has been dosed in our Ph2b BUOY-1 study of GlyphAllo™ (SPT-300) in #MDD w/ or w/o anxious distress, an important milestone for Seaport’s pipeline that brings us closer to a potential new treatment for patients w/ MDD: bit.ly/3Uhn3YB
July 17, 2025 at 11:02 AM
Pleased to announce the first patient has been dosed in our Ph2b BUOY-1 study of GlyphAllo™ (SPT-300) in #MDD w/ or w/o anxious distress, an important milestone for Seaport’s pipeline that brings us closer to a potential new treatment for patients w/ MDD: bit.ly/3Uhn3YB
The Seaport crew kicked off summer with a fun gathering! Great opportunity to connect out of the office, strengthening our mission to develop life-changing medicines for #neuropsychiatric disorders. Looking forward to more moments together and progress towards transforming lives!
June 30, 2025 at 1:27 PM
The Seaport crew kicked off summer with a fun gathering! Great opportunity to connect out of the office, strengthening our mission to develop life-changing medicines for #neuropsychiatric disorders. Looking forward to more moments together and progress towards transforming lives!
Our Co-founder & Board Chair Dr. Steve Paul was at Royalty Pharma’s #ABI25 for a fireside chat on the neuropsych renaissance. A pioneer in neuropsychiatric drug development, he shared insights into this new era of CNS medicines, including Seaport’s work in #depression & #anxiety
June 25, 2025 at 1:37 PM
Our Co-founder & Board Chair Dr. Steve Paul was at Royalty Pharma’s #ABI25 for a fireside chat on the neuropsych renaissance. A pioneer in neuropsychiatric drug development, he shared insights into this new era of CNS medicines, including Seaport’s work in #depression & #anxiety
As #MentalHealthMonth closes, we welcomed a @namicommunicate.bsky.social patient representative to share his journey w/ mental health conditions. His story inspires our work at Seaport to help those struggling & develop new medicines for #depression & #anxiety. More: www.nami.org
May 30, 2025 at 11:04 AM
As #MentalHealthMonth closes, we welcomed a @namicommunicate.bsky.social patient representative to share his journey w/ mental health conditions. His story inspires our work at Seaport to help those struggling & develop new medicines for #depression & #anxiety. More: www.nami.org